Multivariate analysis of TRM and relapse
| . | n . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| TRM | |||
| Donor type | < .001 | ||
| Matched sibling | 212 | 1.00 | |
| URD, well-matched | 249 | 1.55 (1.02-2.37)* | |
| URD, partially-matched | 99 | 3.03 (1.94-4.75)* | |
| GVHD prophylaxis | .002 | ||
| CsA ± other | 277 | 1.00 | |
| Tac ± other | 225 | 0.48 (0.31-0.72)* | |
| T-cell depletion | 46 | 1.07 (0.61-1.88) | |
| Other/missing | 12 | 2.38 (0.95-5.99) | |
| Prior MDS | |||
| No | 452 | 1.00 | |
| Yes | 108 | 1.63 (1.11-2.41) | .01 |
| Growth factor used to promote engraftment | |||
| No | 283 | 1.00 | |
| Yes | 184 | 1.70 (1.17-2.47)* | .005 |
| Missing | 93 | 1.09 (0.65-1.82) | |
| Graft type | |||
| In first 3 mo after treatment | |||
| BM | 228 | 1.00 | |
| PBPC | 332 | 0.55 (0.32-0.95) | .03 |
| After 3 mo after treatment | |||
| BM | 174 | 1.00 | |
| PBPC | 272 | 1.16 (0.70-1.94) | .561 |
| Age and conditioning regimen | |||
| In first 3 mo after treatment | .6 | ||
| 20-50 y, myeloablative | 252 | 1.00 | |
| Less than 20 y, myeloablative | 84 | 0.61 (0.3-1.26) | |
| More than 50 y, myeloablative | 82 | 0.63 (0.28-1.43) | |
| 50 y or less, RIC | 34 | 0.81 (0.25-2.69) | |
| More than 50 y, RIC | 108 | 0.76 (0.37-1.57) | |
| After 3 mo after treatment | < .001 | ||
| 20-50 y, myeloablative | 204 | 1.00 | |
| Less than 20 y, myeloablative | 68 | 0.34 (0.12-0.99)* | |
| More than 50 y, myeloablative | 69 | 2.66 (1.50-4.73)* | |
| 50 y or less, RIC | 29 | 1.15 (0.4-3.32) | |
| More than 50 y, RIC | 76 | 2.84 (1.55-5.23)* | |
| Relapse | |||
| Donor type | .5 | ||
| Matched sibling | 212 | 1.00 | |
| URD, well-matched | 249 | 1.04 (0.76-1.42) | |
| URD, partially-matched | 99 | 0.78 (0.48-1.24) | |
| Donor-recipient sex match | .002 | ||
| Male-male | 204 | 1.00 | |
| Male-female | 152 | 0.66 (0.47-0.94)* | |
| Female-male | 108 | 0.48 (0.31-0.73)* | |
| Female-female | 96 | 0.6 (0.39-0.92)* | |
| Age and conditioning regimen | < .001 | ||
| 20-50 y, myeloablative | 252 | 1.00 | |
| Less than 20 y, myeloablative | 84 | 1.13 (0.73-1.73) | |
| More than 50 y, myeloablative | 82 | 1.3 (0.81-2.08) | |
| 50 y or less, RIC | 34 | 1.3 (0.7-2.4) | |
| More than 50 y, RIC | 108 | 3.08 (1.96-4.83)* | |
| Acute GVHD | |||
| No | 288 | 1.00 | |
| Yes | 272 | 0.99 (0.74-1.33) | .96 |
| Chronic GVHD | |||
| No | 331 | 1.00 | |
| Yes | 229 | 0.68 (0.47-0.99) | .046 |
| . | n . | Relative risk (95% CI) . | P . |
|---|---|---|---|
| TRM | |||
| Donor type | < .001 | ||
| Matched sibling | 212 | 1.00 | |
| URD, well-matched | 249 | 1.55 (1.02-2.37)* | |
| URD, partially-matched | 99 | 3.03 (1.94-4.75)* | |
| GVHD prophylaxis | .002 | ||
| CsA ± other | 277 | 1.00 | |
| Tac ± other | 225 | 0.48 (0.31-0.72)* | |
| T-cell depletion | 46 | 1.07 (0.61-1.88) | |
| Other/missing | 12 | 2.38 (0.95-5.99) | |
| Prior MDS | |||
| No | 452 | 1.00 | |
| Yes | 108 | 1.63 (1.11-2.41) | .01 |
| Growth factor used to promote engraftment | |||
| No | 283 | 1.00 | |
| Yes | 184 | 1.70 (1.17-2.47)* | .005 |
| Missing | 93 | 1.09 (0.65-1.82) | |
| Graft type | |||
| In first 3 mo after treatment | |||
| BM | 228 | 1.00 | |
| PBPC | 332 | 0.55 (0.32-0.95) | .03 |
| After 3 mo after treatment | |||
| BM | 174 | 1.00 | |
| PBPC | 272 | 1.16 (0.70-1.94) | .561 |
| Age and conditioning regimen | |||
| In first 3 mo after treatment | .6 | ||
| 20-50 y, myeloablative | 252 | 1.00 | |
| Less than 20 y, myeloablative | 84 | 0.61 (0.3-1.26) | |
| More than 50 y, myeloablative | 82 | 0.63 (0.28-1.43) | |
| 50 y or less, RIC | 34 | 0.81 (0.25-2.69) | |
| More than 50 y, RIC | 108 | 0.76 (0.37-1.57) | |
| After 3 mo after treatment | < .001 | ||
| 20-50 y, myeloablative | 204 | 1.00 | |
| Less than 20 y, myeloablative | 68 | 0.34 (0.12-0.99)* | |
| More than 50 y, myeloablative | 69 | 2.66 (1.50-4.73)* | |
| 50 y or less, RIC | 29 | 1.15 (0.4-3.32) | |
| More than 50 y, RIC | 76 | 2.84 (1.55-5.23)* | |
| Relapse | |||
| Donor type | .5 | ||
| Matched sibling | 212 | 1.00 | |
| URD, well-matched | 249 | 1.04 (0.76-1.42) | |
| URD, partially-matched | 99 | 0.78 (0.48-1.24) | |
| Donor-recipient sex match | .002 | ||
| Male-male | 204 | 1.00 | |
| Male-female | 152 | 0.66 (0.47-0.94)* | |
| Female-male | 108 | 0.48 (0.31-0.73)* | |
| Female-female | 96 | 0.6 (0.39-0.92)* | |
| Age and conditioning regimen | < .001 | ||
| 20-50 y, myeloablative | 252 | 1.00 | |
| Less than 20 y, myeloablative | 84 | 1.13 (0.73-1.73) | |
| More than 50 y, myeloablative | 82 | 1.3 (0.81-2.08) | |
| 50 y or less, RIC | 34 | 1.3 (0.7-2.4) | |
| More than 50 y, RIC | 108 | 3.08 (1.96-4.83)* | |
| Acute GVHD | |||
| No | 288 | 1.00 | |
| Yes | 272 | 0.99 (0.74-1.33) | .96 |
| Chronic GVHD | |||
| No | 331 | 1.00 | |
| Yes | 229 | 0.68 (0.47-0.99) | .046 |
In each comparison group, P values reflect an overall significant difference between the groups. Because of interactions between age and conditioning regimen as well as nonproportional hazards over time, TRM was analyzed by time periods as shown.
Tac indicates tacrolimus; and BM, bone marrow.
Significantly different value from the reference group.